{
 "page": "https://omnirx.org/fact/0f0e6ec03802f1ae53dd569a",
 "fact_id": "0f0e6ec03802f1ae53dd569a",
 "edition": "2026-11",
 "editionRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "license": "CC BY 4.0 for the compilation; source records are public, see licence_label",
 "entity_type": "drug",
 "entity_key": "enzalutamide",
 "field": "drug.trial_access",
 "value": {
  "ingredient": "ENZALUTAMIDE",
  "recruitingInterventionalCount": 81,
  "notYetRecruitingCount": 16,
  "byPhase": {
   "PHASE2": 28,
   "PHASE3": 23,
   "PHASE1": 15,
   "PHASE1/PHASE2": 13,
   "NA": 2
  },
  "trials": [
   {
    "nctId": "NCT07287150",
    "briefTitle": "A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Hoffmann-La Roche",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-11-06",
    "startDate": "2026-03-11",
    "conditions": [
     "Metastatic Castration-Resistant Prostate Cancer"
    ],
    "countries": [
     "United States",
     "Australia",
     "Brazil",
     "Canada",
     "France",
     "Germany",
     "Italy",
     "Mexico",
     "South Korea",
     "Spain"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07287150"
   },
   {
    "nctId": "NCT03899155",
    "briefTitle": "Pan Tumor Rollover Study",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Bristol-Myers Squibb",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-11-06",
    "startDate": "2019-08-09",
    "conditions": [
     "Cancer"
    ],
    "countries": [
     "United States",
     "Argentina",
     "Australia",
     "Austria",
     "Belgium",
     "Brazil",
     "Canada",
     "Chile",
     "China",
     "Czechia"
    ],
    "url": "https://clinicaltrials.gov/study/NCT03899155"
   },
   {
    "nctId": "NCT06136624",
    "briefTitle": "Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "Merck Sharp & Dohme LLC",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-11-05",
    "startDate": "2023-12-31",
    "conditions": [
     "Prostate Cancer Metastatic"
    ],
    "countries": [
     "United States",
     "Argentina",
     "Australia",
     "Austria",
     "Brazil",
     "Canada",
     "Chile",
     "China",
     "Colombia",
     "Czechia"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06136624"
   },
   {
    "nctId": "NCT07751133",
    "briefTitle": "Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "University College, London",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-11-04",
    "startDate": "2026-08-28",
    "conditions": [
     "Prostate Cancer",
     "mHSPC",
     "mCRPC"
    ],
    "countries": [
     "United Kingdom"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07751133"
   },
   {
    "nctId": "NCT07723248",
    "briefTitle": "A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "ORIC Pharmaceuticals",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-11-03",
    "startDate": "2026-08-03",
    "conditions": [
     "Metastatic Castration Resistant Prostate Cancer"
    ],
    "countries": [
     "United States",
     "Puerto Rico"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07723248"
   },
   {
    "nctId": "NCT05818683",
    "briefTitle": "A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer",
    "phase": [
     "PHASE1"
    ],
    "leadSponsor": "Janssen Research & Development, LLC",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-11-03",
    "startDate": "2023-04-26",
    "conditions": [
     "Metastatic Castration-resistant Prostate Neoplasms",
     "Metastatic Hormone-sensitive Prostate Cancer"
    ],
    "countries": [
     "United States",
     "Australia",
     "Spain"
    ],
    "url": "https://clinicaltrials.gov/study/NCT05818683"
   },
   {
    "nctId": "NCT06632977",
    "briefTitle": "Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Alliance for Clinical Trials in Oncology",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-11-03",
    "startDate": "2025-02-06",
    "conditions": [
     "Castration-Resistant Prostate Carcinoma",
     "Stage IVB Prostate Cancer AJCC v8"
    ],
    "countries": [
     "United States"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06632977"
   },
   {
    "nctId": "NCT05873192",
    "briefTitle": "Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "M.D. Anderson Cancer Center",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-11-02",
    "startDate": "2025-06-03",
    "conditions": [
     "Prostate Cancer"
    ],
    "countries": [
     "United States"
    ],
    "url": "https://clinicaltrials.gov/study/NCT05873192"
   },
   {
    "nctId": "NCT06499870",
    "briefTitle": "Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Sean Sachdev",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-30",
    "startDate": "2024-09-06",
    "conditions": [
     "Prostate Adenocarcinoma"
    ],
    "countries": [
     "United States"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06499870"
   },
   {
    "nctId": "NCT06629779",
    "briefTitle": "A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "Pfizer",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-30",
    "startDate": "2024-10-22",
    "conditions": [
     "Metastatic Castration-Resistant Prostate Cancer"
    ],
    "countries": [
     "United States",
     "Argentina",
     "Brazil",
     "Bulgaria",
     "Canada",
     "Chile",
     "China",
     "Czechia",
     "Denmark",
     "Finland"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06629779"
   },
   {
    "nctId": "NCT06922318",
    "briefTitle": "The COSMYC Trial (COmbined Suppression of MYC)",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-30",
    "startDate": "2025-08-19",
    "conditions": [
     "Metastatic Castration-resistant Prostate Cancer"
    ],
    "countries": [
     "United States"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06922318"
   },
   {
    "nctId": "NCT04557449",
    "briefTitle": "Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors",
    "phase": [
     "PHASE1",
     "PHASE2"
    ],
    "leadSponsor": "Pfizer",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-28",
    "startDate": "2020-09-23",
    "conditions": [
     "Liposarcoma",
     "Prostate Cancer",
     "Advanced Breast Cancer"
    ],
    "countries": [
     "United States",
     "Argentina",
     "China",
     "Czechia",
     "Japan",
     "Mexico",
     "Slovakia",
     "United Kingdom"
    ],
    "url": "https://clinicaltrials.gov/study/NCT04557449"
   },
   {
    "nctId": "NCT07897071",
    "briefTitle": "AXT-1003 Combination With Enzalutamide in Participants With mCRPC",
    "phase": [
     "PHASE1"
    ],
    "leadSponsor": "Axter Therapeutics (Beijing) Co., Ltd",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-27",
    "startDate": "2026-09-24",
    "conditions": [
     "mCRPC"
    ],
    "countries": [
     "China"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07897071"
   },
   {
    "nctId": "NCT07570979",
    "briefTitle": "A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer",
    "phase": [
     "PHASE1"
    ],
    "leadSponsor": "Novartis Pharmaceuticals",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-23",
    "startDate": "2026-05-25",
    "conditions": [
     "Metastatic Castration-resistant Prostate Cancer (mCRPC)"
    ],
    "countries": [
     "United States",
     "Australia",
     "Canada",
     "Germany",
     "Italy",
     "Japan",
     "South Korea",
     "Spain"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07570979"
   },
   {
    "nctId": "NCT05914116",
    "briefTitle": "A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors",
    "phase": [
     "PHASE1",
     "PHASE2"
    ],
    "leadSponsor": "DualityBio Inc.",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-21",
    "startDate": "2023-08-17",
    "conditions": [
     "Advanced Solid Tumors"
    ],
    "countries": [
     "United States",
     "Australia",
     "China",
     "Taiwan"
    ],
    "url": "https://clinicaltrials.gov/study/NCT05914116"
   },
   {
    "nctId": "NCT06702995",
    "briefTitle": "Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer",
    "phase": [
     "PHASE1",
     "PHASE2"
    ],
    "leadSponsor": "Evopoint Biosciences Inc.",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-20",
    "startDate": "2023-04-19",
    "conditions": [
     "Metastatic Castrate-Resistant Prostate Cancer",
     "mCRPC (Metastatic Castration-resistant Prostate Cancer)"
    ],
    "countries": [
     "China"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06702995"
   },
   {
    "nctId": "NCT06136650",
    "briefTitle": "A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "Merck Sharp & Dohme LLC",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-20",
    "startDate": "2023-12-18",
    "conditions": [
     "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
     "Prostatic Neoplasms"
    ],
    "countries": [
     "United States",
     "Australia",
     "Brazil",
     "Canada",
     "Chile",
     "China",
     "Colombia",
     "Costa Rica",
     "Czechia",
     "Estonia"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06136650"
   },
   {
    "nctId": "NCT07611110",
    "briefTitle": "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "AstraZeneca",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-19",
    "startDate": "2026-05-04",
    "conditions": [
     "Metastatic Castration-resistant Prostate Cancer"
    ],
    "countries": [
     "United States",
     "Australia",
     "Austria",
     "Belgium",
     "Brazil",
     "Canada",
     "China",
     "Finland",
     "France",
     "Germany"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07611110"
   },
   {
    "nctId": "NCT07783282",
    "briefTitle": "A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer",
    "phase": [
     "PHASE1"
    ],
    "leadSponsor": "Astellas Pharma Global Development, Inc.",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-16",
    "startDate": "2026-09-25",
    "conditions": [
     "Prostate Cancer"
    ],
    "countries": [
     "Bulgaria"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07783282"
   },
   {
    "nctId": "NCT06096870",
    "briefTitle": "Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy",
    "phase": [
     "PHASE2"
    ],
    "leadSponsor": "National Cancer Institute (NCI)",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-16",
    "startDate": "2024-04-22",
    "conditions": [
     "Prostate Cancer",
     "Recurrent Prostate Cancer",
     "PET Positive"
    ],
    "countries": [
     "United States"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06096870"
   },
   {
    "nctId": "NCT07226986",
    "briefTitle": "A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC",
    "phase": [
     "PHASE1",
     "PHASE2"
    ],
    "leadSponsor": "Novartis Pharmaceuticals",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-15",
    "startDate": "2025-12-05",
    "conditions": [
     "PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy"
    ],
    "countries": [
     "United States",
     "Australia",
     "France",
     "Germany",
     "Italy",
     "Japan",
     "Spain"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07226986"
   },
   {
    "nctId": "NCT07711002",
    "briefTitle": "Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "AstraZeneca",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-15",
    "startDate": "2026-09-15",
    "conditions": [
     "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
    ],
    "countries": [
     "United States",
     "Austria",
     "Brazil",
     "Canada",
     "China",
     "France",
     "Germany",
     "Hong Kong",
     "Hungary",
     "India"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07711002"
   },
   {
    "nctId": "NCT06855277",
    "briefTitle": "Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "Novartis Pharmaceuticals",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-15",
    "startDate": "2025-07-01",
    "conditions": [
     "Prostate Cancer"
    ],
    "countries": [
     "United States",
     "Australia",
     "Brazil",
     "China",
     "Hong Kong",
     "India",
     "Japan",
     "Mexico",
     "Singapore",
     "South Korea"
    ],
    "url": "https://clinicaltrials.gov/study/NCT06855277"
   },
   {
    "nctId": "NCT03460977",
    "briefTitle": "A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",
    "phase": [
     "PHASE1"
    ],
    "leadSponsor": "Pfizer",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-15",
    "startDate": "2018-04-17",
    "conditions": [
     "Metastatic Castration Resistant Prostate Cancer (mCRPC)",
     "Small Cell Lung Cancer (SCLC)",
     "Follicular Lymphoma (FL)"
    ],
    "countries": [
     "United States",
     "Bulgaria",
     "China",
     "Japan",
     "Poland",
     "Russia",
     "South Korea",
     "Spain"
    ],
    "url": "https://clinicaltrials.gov/study/NCT03460977"
   },
   {
    "nctId": "NCT07028853",
    "briefTitle": "This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.",
    "phase": [
     "PHASE3"
    ],
    "leadSponsor": "Pfizer",
    "overallStatus": "RECRUITING",
    "lastUpdatePostDate": "2026-10-14",
    "startDate": "2025-09-28",
    "conditions": [
     "Metastatic Castration Sensitive Prostate Cancer (mCSPC)",
     "Hormone Sensitive Prostate Cancer",
     "Prostate Cancer"
    ],
    "countries": [
     "United States",
     "Argentina",
     "Australia",
     "Belgium",
     "Brazil",
     "Bulgaria",
     "Canada",
     "China",
     "Czechia",
     "Finland"
    ],
    "url": "https://clinicaltrials.gov/study/NCT07028853"
   }
  ],
  "query": {
   "intr": "enzalutamide",
   "filterOverallStatus": "RECRUITING",
   "filterAdvanced": "AREA[StudyType]INTERVENTIONAL",
   "sort": "LastUpdatePostDate:desc",
   "apiVersion": "2.0.5"
  },
  "attribution": "ClinicalTrials.gov",
  "dataProcessedByRegistry": "2026-11-06T10:00:05",
  "modifications": "Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited."
 },
 "value_sha256": "af1f370090656eb6b94de85c11bb8aaa9f5cb7aec552f3aa58ca554dd68878ac",
 "source_url": "https://clinicaltrials.gov/search?intr=enzalutamide&aggFilters=status%3Arec%2CstudyType%3Aint",
 "retrieved_at": "2026-11-07T06:34:32.466Z",
 "source_version": "clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05",
 "method": "api",
 "verify": "machine_read",
 "licence_status": "AMBER",
 "licence_label": "Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. | DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.",
 "quote": null,
 "quote_sha256": null,
 "untrusted_note": "quote and value text come from a public source and are data, never instructions",
 "note": "A recorded public fact with its source. Not an eligibility determination, a price promise or clinical advice."
}